[Epidemiological Analysis and Economic Burden of Gastric and Gastroesophageal Junction Neoplasms in Italy]
DOI:
https://doi.org/10.7175/fe.v27i1.1606Keywords:
Gastric cancer, Gastroesophageal junction cancer, Epidemiology, Healthcare costs, Administrative data, Real-world evidenceAbstract
OBJECTIVES: To estimate the epidemiological distribution and economic impact of gastric and gastroesophageal junction
neoplasms in Italy.
METHODS: Retrospective transversal and longitudinal analyses were conducted using the Italian Hospital Discharge Records
from 2010 to 2019, and the administrative databases of the Umbria 2 Local Health Unit for the period 2014–2018. Patients
were stratified by disease stage. Incidence, prevalence, in-hospital mortality, and progression patterns were estimated.
Cost analyses included hospitalizations, outpatient specialist services, and pharmaceutical expenditures, based on regional
tariffs. The methodology and findings were validated through two structured discussions with Key Opinion Leaders from
northern, central, and southern Italy.
RESULTS: The national incidence and mortality decreased over time, while prevalence showed a peak in 2017. A marked
regional variability in hospitalization rates was noted, reflecting differences in healthcare practices rather than underlying
epidemiology. The trend toward decreased mortality was not confirmed by the analysis in Umbria 2 Health Authority,
which accounted also for non-hospital mortality. Average annual per-patient costs borne by the Italian National Health
Service (NHS) were €12,797, €18,505, and €15,173 for localized, locally advanced, and metastatic disease, respectively.
Hospitalization costs accounted for over 88% of expenses. One-year mortality reached 74% in the metastatic group. As the
period considered predates the widespread adoption of high-cost targeted therapies and immunotherapies, current costs are
likely underestimated.
CONCLUSIONS: Gastric and gastroesophageal junction cancers remain a significant burden for the Italian NHS in terms
of both clinical outcomes and healthcare spending. This study offers an integrated national and regional perspective on
the real-world impact of these diseases, reinforcing the need for improved data integration, early detection strategies, and
resource planning tailored to future therapeutic developments.
Published
Issue
Section
License
Copyright (c) 2026 Paolo Sciattella, Angela Ragonese, Rossana Berardi, Maria Di Bartolomeo, Evaristo Maiello, Paolo Di Rienzo, Fausto Bartolini, Andrea Marcellusi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
